StemCells (STEM) Misses Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. SPY
3. CRWV
4. BAC
5. RKLB
6. BLK
7. NOW
8. CAT
9. RXRX
10. MSFT

Go back to StemCells (STEM) Misses Q3 EPS by 2c

StemCells, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update

March 16, 2015 4:05 PM EDT

NEWARK, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2014.

"We achieved three significant clinical translation milestones in 2014: the completion of enrollment in two Phase I/II studies and initiation of the first of two planned, multicenter Phase II proof of concept studies using our proprietary human neural stem cell platform," said Martin McGlynn, President... More